Sodium-Glucose Cotransporter-2 Inhibitors: Elevating Standards in Cardiovascular Secondary Prevention.

The article argues for elevating the standards in cardiovascular secondary prevention, with reference to a study which explored the association of treatment with sodium-glucose cotransporter-2 inhibitors and reduced risk of atrial fibrillation occurrence after catheter ablation in patients with type 2 diabetes mellitus.